PATIENTS AFFECTED BY ALS MedDRA version: 9.1 Level: PT Classification code 10002026
Conditions
Interventions
Pharmaceutical Form: Solution for injection
INN or Proposed INN: Edetates
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 1-
Sponsors
Dr.ssa Marina Aiello-Universit? degli studi di Parma
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: a.Certained ALS dignosis, probable or probable and laboratory tests supported ALS diagnosis. b.Age > 18 years c.Written informed consent. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: a.Former poliomyelitis b.Other motor neuron disease c.Patients unable to give their written informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The aim of this study is to evaluate heavy metal poisoning in patients affected by ALS admitted to our out-patients clinic.;Secondary Objective: To assess the role of heavy metal poisoning in the progression of ALS in order to suggest other therapeutic strategies.;Primary end point(s): The aim of this study is to evaluate heavy metal poisoning in patients affected by ALS admitted to our out-patients clinic. | — |
Countries
Italy
Outcome results
None listed